Verastem, Inc. is a late-stage development biopharmaceutical company, which focuses on the development and commercialization of new medicines to improve the lives of patients diagnosed with ras sarcoma (RAS)/ mitogen-activated pathway kinase (MAPK) pathway-driven cancers. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.
Growing
The company is in a growing phase, with the latest annual income totaling USD 30.91M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 30.91M.
Fairly Valued
The company’s latest PE is -1.85, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 83.43M shares, increasing 1.27% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 37.30K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.47.